Skip to main content
Medical information Clinical review pending

Genetic Testing

CTDP1 Gene CMT4 CTDP1 Related Genetic Test

Genetic test to identify mutations in the CTDP1 gene associated with Charcot-Marie-Tooth disease (CMT), a neurological disorder. Helps in diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CTDP1 Gene CMT4 CTDP1 Related Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals experiencing symptoms suggestive of Charcot-Marie-Tooth disease (e.g., muscle weakness, foot deformities, sensory loss).
  • ✓Family history of Charcot-Marie-Tooth disease.
  • ✓Genetic counseling for inherited neurological disorders.
  • ✓Confirmation of diagnosis when clinical presentation is unclear.
02

In plain language

What this test helps you understand

This test helps confirm or rule out a diagnosis of Charcot-Marie-Tooth disease (CMT) related to the CTDP1 gene. It can aid in understanding the genetic basis of the condition, guiding management, and providing information for family planning.
The CTDP1 Gene CMT4 CTDP1 Related NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to Charcot-Marie-Tooth disease (CMT). CMT is a group of inherited neurological disorders affecting the peripheral nerves. This test uses Next Generation Sequencing (NGS) technology to analyze the CTDP1 gene.

Early diagnosis through genetic testing is important for individuals experiencing symptoms like muscle weakness, atrophy, or sensory loss. Identifying the specific genetic cause can help guide management strategies and improve quality of life.

This test specifically looks for mutations within the CTDP1 gene that are known to cause certain types of CMT. By analyzing a DNA sample, the test can detect variations that may indicate a predisposition to this disorder.

Results interpretation requires expertise. A genetic counselor can help explain the findings and their implications for your health and family.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the CTDP1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the CTDP1 gene. It may not detect mutations in other genes associated with CMT or other neurological conditions. A negative result does not completely rule out CMT if symptoms persist. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CMT is a group of inherited disorders that affect the peripheral nerves, leading to muscle weakness, sensory loss, and foot deformities.
This test helps identify the specific genetic cause of CMT related to the CTDP1 gene, leading to an accurate diagnosis and better management.
Individuals with symptoms of CMT or a family history of the condition should discuss this test with their doctor.
Results should be interpreted by a qualified healthcare professional, often in consultation with a genetic counselor, to understand their implications.
The test involves analyzing a DNA sample, typically obtained from a blood sample.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp